Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$2.28
<$0.01(0.49%)
At close: 4:00 PM EDT
$2.28
<$0.01(0.49%)
Day’s Range― - ―
52-Week Range$1.08 - $2.95
Previous CloseN/A
Volume8.02K
Average Volume (3M)17.57K
Market Cap
$21.76M
Enterprise Value$22.10M
Total Cash (Recent Filing)$9.19M
Total Debt (Recent Filing)$5.56M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding11,574,362
10 Day Avg. Volume19,499
30 Day Avg. Volume17,574
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue6.76
Enterprise Value/Gross Profit7.52
Enterprise Value/Ebitda-5.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationPositive TTM operating and free cash flow of $3.12M marks a meaningful recovery from deeply negative operating cash flow in 2023. Continued cash generation would give the royalty-focused business more capacity to fund obligations and preserve strategic flexibility without relying solely on external capital.
Modest LeverageDebt of $5.56M versus $27.13M of equity produces modest leverage near 0.20, with leverage improved from 2023–2024. This stronger capital structure and positive equity reduce near-term solvency pressure and leave more room to manage volatility while the company relies on royalties.
Lean Royalty-Focused ModelA lean royalty-collection model can reduce the operating burden associated with traditional pharmaceutical development and direct commercialization. If existing licensed products continue generating royalties, this structure may support cash preservation and allow management to focus resources on asset monetization.
Bears Say
Declining Revenue BaseThe company’s revenue base remains small and is contracting, while the latest license revenue also declined year over year. Because royalties are central to the current model, sustained weakness in licensed-product sales could limit cash generation and reduce the business’s ability to support ongoing expenses.
Unproven Operating ProfitabilityMaterially negative EBIT and EBITDA show that the current revenue base does not yet support the company’s operating structure. Higher operating expenses further pressure results, leaving profitability dependent on revenue stabilization and cost discipline rather than demonstrating a durable earnings model.
Strategic UncertaintyThe strategic alternatives review creates uncertainty around the company’s future structure, asset ownership and operating direction. With no fixed timetable or assurance that a transaction will occur, management may face prolonged disruption while shareholders remain exposed to changing strategic priorities.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $1.08 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $21.76M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Nov 17, 2026 which is in 26 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on Aug 11, 2026. The company reported $0.013 earnings per share for the quarter.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.013 in its last earnings report. Following the earnings report the stock price went up 0.483%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.11% Mutual Funds
<0.01% Other Institutional Investors
90.69% Public Companies and
Individual Investors